Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Dana Taghaddos, Iryna Savinova, Mohannad Abu-Hilal
BACKGROUND: Prurigo nodularis (PN) is a complex chronic skin disease characterized by severe pruritic nodules. PN is often associated with mental health disorders and chronic medical comorbidities. Until recently, PN treatment has been challenging and difficult. OBJECTIVES: This study aims to describe the demographic, clinical characteristics, and comorbidities associated with PN. Also, we aim to describe the effectiveness of systemic therapies, including methotrexate, cyclosporine, and narrow band ultraviolet (NB-UVB) in adult patients with PN...
January 28, 2024: Journal of Cutaneous Medicine and Surgery
#22
JOURNAL ARTICLE
Kevin Brunold, Maria Otth, Katrin Scheinemann
IMPORTANCE: Childhood cancer survivors (CCS) are at risk for late effects of different organ systems. The currently available screening recommendations for those treated with high-dose methotrexate (HD-MTX) are not uniform and the available literature is limited. OBJECTIVE: We aim to assess the prevalence and severity of late effects in CCS treated with HD-MTX at a single centre in Switzerland. We focus on organ systems defined at risk by the long-term follow-up care guidelines of the children's oncology group (COG), because this guideline has a holistic approach, is evidence based, and up to date...
January 25, 2024: Discover. Oncology
#23
JOURNAL ARTICLE
Roeland Vis, Harold Mathijssen, Ruth G M Keijsers, Ewoudt M W van de Garde, Marcel Veltkamp, Fatima Akdim, Marco C Post, Jan C Grutters
BACKGROUND: Side effects limit the long-term use of glucocorticoids in cardiac sarcoidosis (CS), and methotrexate has gained attention as steroid sparing agent although the supporting evidence is poor. This study compared prednisone monotherapy, methotrexate monotherapy or a combination of both, in the reduction of myocardial Fluorine-18 fluorodeoxyglucose (FDG) uptake and clinical stabilization of CS patients. METHODS AND RESULTS: In this retrospective cohort study, 61 newly diagnosed and treatment naïve CS patients commenced treatment with prednisone (N = 21), methotrexate (N = 30) or prednisone and methotrexate (N = 10) between January 2010 and December 2017...
August 2023: Journal of Nuclear Cardiology
#24
REVIEW
Jesús Tornero Molina, Blanca Hernández-Cruz, Héctor Corominas
BACKGROUND: We aimed to analyse the effectiveness, efficiency, and safety of initial treatment with biological therapies in rheumatoid arthritis (RA). METHODS: Qualitative study. A group of RA experts was selected. A scoping review in Medline was conducted to analyse the evidence of initial RA treatment with biological therapies. Randomised clinical trials were selected. Two reviewers analysed the articles and compiled the data, whose quality was assessed using the Jadad scale...
December 21, 2023: Journal of Clinical Medicine
#25
JOURNAL ARTICLE
Siyuan Yu, Xian Shao, Tong Wu, Zheng Liu, Pei Yu, Jinfeng Xing
In order to achieve long-term and controllable release of anti-tumor drugs at specific sites, temperature/pH responsive nanoparticles encapsulating 5-fluorouracil (5-FU) and methotrexate (MTX) in situ were prepared through dispersion photopolymerization under green LED irradiation. The physicochemical properties of nanoparticles were characterized by SEM, FTIR, DLS, TG/DSC and XRD. In vitro drug release at different temperatures and pH values was examined to ascertain the release pattern of two drugs, which can be well described by Korsmeyer-Peppas kinetic model...
January 10, 2024: Macromolecular Bioscience
#26
JOURNAL ARTICLE
Antonio Vitale, Valeria Caggiano, Petros P Sfikakis, Lorenzo Dagna, Giuseppe Lopalco, Gaafar Ragab, Francesco La Torre, Ibrahim A Almaghlouth, Maria Cristina Maggio, Jurgen Sota, Abdurrahman Tufan, Andrea Hinojosa-Azaola, Florenzo Iannone, Roberta Loconte, Katerina Laskari, Haner Direskeneli, Piero Ruscitti, Maria Morrone, Henrique A Mayrink Giardini, Alexandros Panagiotopoulos, Ilenia Di Cola, Eduardo Martín-Nares, Sara Monti, Ludovico De Stefano, Rıza Can Kardas, Rahime Duran, Corrado Campochiaro, Alessandro Tomelleri, Abdulaziz Mohammed Alabdulkareem, Carla Gaggiano, Maria Tarsia, Elena Bartoloni, Mery Romeo, Mohamed A Hussein, Ahmed Hatem Laymouna, Isabele Parente de Brito Antonelli, Marilia Ambiel Dagostin, Lampros Fotis, Sara Bindoli, Luca Navarini, Fatma Alibaz-Oner, Gizem Sevik, Micol Frassi, Francesco Ciccia, Daniela Iacono, Francesca Crisafulli, Piero Portincasa, Nour Jaber, Perla Ayumi Kawakami-Campos, Ewa Wiesik-Szewczyk, Annamaria Iagnocco, Gabriele Simonini, Paolo Sfriso, Alberto Balistreri, Roberto Giacomelli, Giovanni Conti, Bruno Frediani, Claudia Fabiani, Luca Cantarini
INTRODUCTION: The effectiveness of canakinumab may change according to the different times it is used after Still's disease onset. This study aimed to investigate whether canakinumab (CAN) shows differences in short- and long-term therapeutic outcomes, according to its use as different lines of biologic treatment. METHODS: Patients included in this study were retrospectively enrolled from the AutoInflammatory Disease Alliance (AIDA) International Registry dedicated to Still's disease...
2023: Frontiers in Medicine
#27
JOURNAL ARTICLE
Paul Jm Sessink, Birgit Tans, Isabel Spriet, David Devolder
INTRODUCTION: Exposure of healthcare workers to hazardous drugs can lead to adverse health effects supporting the importance of a continuous monitoring program, for example, by taking surface wipe samples. The objective was to describe the results of repeated monitoring of contamination with hazardous drugs on multiple surfaces in a hospital pharmacy and at two wards using standardized preparation techniques and cleaning procedures. METHODS: Twelve surfaces in the hospital pharmacy and at two wards were sampled and analyzed for contamination with the hazardous drugs cyclophosphamide, doxorubicin, 5-fluorouracil, gemcitabine, methotrexate, and paclitaxel...
December 19, 2023: Journal of Oncology Pharmacy Practice
#28
JOURNAL ARTICLE
Hirochika Yamasaki, Hidekazu Kondo, Naoko Ogawa, Kazuki Mitarai, Yumi Ishi, Shotaro Saito, Naohiko Takahashi
A 54-year-old woman developed new-onset heart failure and was diagnosed with cardiac sarcoidosis. An implantable cardioverter-defibrillator with biventricular pacing was implanted before immunosuppressive therapy to prevent sudden death. The patient refused oral steroids because she disliked their specific side effects and potential adverse events with long-term use; therefore, methotrexate was chosen as an alternative first-line drug. Nine months after starting oral therapy, 18 F-fluorodeoxyglucose-positron emission tomography revealed remission of sarcoidosis, disappearance of heart failure symptoms, marked improvement in cardiac contractility, and a reduced frequency of ventricular arrhythmias...
December 18, 2023: Internal Medicine
#29
REVIEW
Nicholas T Jones, Camryn L Keller, Raegan B Abadie, Matthew B Bratton, Emmilee J Henderson, Peyton Moore, Ross Rieger, Shahab Ahmadzadeh, Sridhar Tirumala, Giustino Varrassi, Sahar Shekoohi, Alan D Kaye
Polyarticular course juvenile idiopathic arthritis (pcJIA) is a form of arthritis that affects at least five joints at a time and presents before the age of 16. Its most common symptoms are pain, swelling, redness, and a limited range of motion, making it incredibly difficult for patients diagnosed to function in daily life. Historically, the leading treatment options have consisted of non-steroidal anti-inflammatory drugs (NSAIDs) and disease-modifying antirheumatic drugs (DMARDs) such as methotrexate. However, these drugs have serious toxic side effects associated with long-term use in addition to being ineffective in refractory cases...
November 2023: Curēus
#30
JOURNAL ARTICLE
Jiaqiang Wang, Fan Zhang, Shuping Dong, Yang Yang, Fangfang Gao, Guancong Liu, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian
BACKGROUND: Effective adjuvant therapy for osteosarcoma is necessary for improved outcomes. Previous studies demonstrated that apatinib plus doxorubicin-based chemotherapy may improve the efficacy of neoadjuvant therapy. This study aimed to clarify the effectiveness and safety of apatinib plus doxorubicin and cisplatin (AP) as neoadjuvant therapy for osteosarcoma. METHODS: The clinical data of osteosarcoma patients who underwent neoadjuvant therapy and surgery between August 2016 and April 2022 were retrospectively collected and analyzed...
2023: Frontiers in Oncology
#31
JOURNAL ARTICLE
Hana Smajlović, Asja Prohić
For over two decades, the acronym PAPA syndrome has been used to describe an autoinflammatory condition caused by missense mutations in the PSTPIP1 (proline-serine-threonine phosphatase interacting protein 1) gene and clinically characterized by the presence of pyogenic arthritis, pyoderma gangrenosum (PG), and acne (1,2). Due to the involvement of the PSTPIP1 gene in the regulation of innate immunity, mutations of this gene cause abnormal activation of inflammasomes, complexes of NLRP3/ASC/caspase-1 proteins...
November 2023: Acta Dermatovenerologica Croatica: ADC
#32
JOURNAL ARTICLE
Alicja Mesjasz, Magdalena Trzeciak, Jowita Sroka-Tomaszewska, Anna Zaryczańska, Roman J Nowicki
Dear Editor, A 41-year-old man presented to the Department of Dermatology for the first time due to an exacerbation of atopic dermatitis (AD) in the form of erythroderma. The patient had a history of atopic diseases, with being AD active from infancy. On clinical examination, generalized erythematous skin lesions causing acute pruritus and accompanied by severe skin exfoliation and dryness were present. On closer examination, the patient had a collection of signs and symptoms characterizing Cushing syndrome that included a round and full face (''moon face''), supraclavicular fat pads, and proximal muscle atrophy...
November 2023: Acta Dermatovenerologica Croatica: ADC
#33
JOURNAL ARTICLE
Jing Gao, Xiaoyan Peng, Liang Wang
BACKGROUND: Vitreoretinal lymphoma (VRL) is usually treated with a combination of intraocular methotrexate (ioMTX), high-dose intravenous methotrexate (HD-MTX), or local radiotherapy (RT) as the first options. The effectiveness and safety of monotherapy like bruton's tyrosine kinase inhibitors (BTKi) for PVRL remain uncertain. METHODS: A systematic review and meta-analysis of clinical trial data and conference abstracts in VRL patients treated with first-line combination therapy or monotherapy were conducted through a search of PubMed, Embase, and Scopus databases until December 2022...
November 22, 2023: BMC Ophthalmology
#34
REVIEW
Lillian E McCampbell, Mallory L Zaino, Manas Ranpariya, Tejesh Patel, Steven R Feldman
IMPORTANCE: Prurigo nodularis (PN) is a debilitating inflammatory skin disease characterized by red to violaceous pruritic lesions. The goal of therapy is to break the scratch-itch cycle. Treatment varies and often requires a multimodal approach to target both immune and neural mediated aspects of disease. OBJECTIVES: To review the efficacy of systemic treatment used to treat PN. EVIDENCE REVIEW: A systematic search of keywords and Medical Subject Headings was performed in Ovid MEDLINE, Embase, Scopus, and ClinicalTrials...
November 2023: Journal of Cutaneous Medicine and Surgery
#35
JOURNAL ARTICLE
Sascha Louise Heckert, Johanna Maria Maassen, S le Cessie, Y P M Goekoop-Ruiterman, Melek Güler-Yüksel, Willem Lems, Tom Wj Huizinga, Sytske Anne Bergstra, Cornelia F Allaart
OBJECTIVES: To study long-term (up to 20-year) mortality of two treat-to-target trial cohorts in undifferentiated arthritis (UA) and early rheumatoid arthritis (RA). METHODS: The BeSt (BehandelStrategieën) study (n=508, early RA) was performed between 2000 and 2012. For 10 years, patients were treated-to-target disease activity score (DAS)≤2.4.The Induction therapy with Methotrexate and Prednisone in Rheumatoid Or Very Early arthritic Disease (IMPROVED) study (n=610, early RA/UA) was performed between 2007 and 2015...
November 18, 2023: Annals of the Rheumatic Diseases
#36
REVIEW
Qiaohong Wang, Liheng Chen
Of the 15 eligible studies identified via electronic searches in MEDLINE, EMBASE and CENTRAL in November 2022 for methotrexate therapy of moderate-to-severe atopic dermatitis, 12 were non-randomized controlled trial (non-RCT) studies with data from 437 patients (235 adults and 202 children). The response rates for short-term therapy were 77% [95% CI 55-99] (four studies; adults) - comparable to 81% [54-100] of RCTs (two studies; adults) (p = 0.63) - and 61% [43-79] (two studies; children), and for medium/long-term therapy were 88...
November 8, 2023: Australasian Journal of Dermatology
#37
JOURNAL ARTICLE
Alice Bergamini, Ramya Ramaswami, Fieke Froeling, Panos Papanastasopoulos, Dee Short, Xianne Aguiar, Philip M Savage, Naveed Sarwar, Baljeet Kaur, Srdjan Saso, Christina Fotopoulou, Anand Sharma, Gordon John Sampson Rustin, Michael Seckl
OBJECTIVE: To assess fertility outcomes in long-term survivors of malignant ovarian germ cell tumors treated with fertility-sparing surgery with or without additional chemotherapy. METHODS: Women diagnosed and treated for malignant ovarian germ cell tumors at Charing Cross Hospital or Mount Vernon Cancer Centre between 1977 and 2015 were included. Questionnaires assessing fertility issues were sent to patients treated with fertility-sparing surgery. Fertility outcomes were evaluated according to the treatment received...
November 6, 2023: International Journal of Gynecological Cancer
#38
JOURNAL ARTICLE
Tsutomu Takeuchi, Yukihiro Chino, Yoko Mano, Masafumi Kawanishi, Yuri Sato, Saeko Uchida, Yoshiya Tanaka
Ozoralizumab is a bispecific NANOBODY® compound that binds tumor necrosis factor alpha (TNFα) and human serum albumin (HSA). Ozoralizumab inhibits the TNFα physiological activity while maintaining long-term plasma retention owing to its HSA-binding ability. A population pharmacokinetic (PK) model was developed using data from 494 Japanese patients with rheumatoid arthritis (RA) in phase II/III and phase III trials to assess the effects of potential PK covariates. The ozoralizumab PK after subcutaneous administration was described using a one-compartment model with first-order absorption and first-order elimination processes...
November 1, 2023: Journal of Clinical Pharmacology
#39
JOURNAL ARTICLE
Kentaro Watanabe
Central nervous system relapse prevention through intrathecal and intravenous methotrexate (MTX) administration is a crucial aspect of treatment in acute lymphoblastic leukemia. However, neurotoxicity-induced leukoencephalopathy is a significant concern. Neurological symptoms associated with MTX can appear as subacute leukoencephalopathies, which manifest as a stroke-like syndrome, consisting of paralysis, seizures, consciousness disturbances, and dysarthria. These symptoms persist for a few days, presenting with fluctuating severity and location...
2023: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
#40
JOURNAL ARTICLE
Hemi Luan, Shuailong Chen, Longshan Zhao, Shijia Liu, Tiangang Luan
Rheumatoid arthritis (RA) is a long-term autoimmune condition that causes joint and surrounding tissue inflammation. Lipid mediators are involved in inflammation and deterioration of the joints. Despite attempts to discover effective drug targets to intervene with lipid metabolism in the disease, progress has been limited. In this study, precise lipidomic technology was employed to quantify a broad range of serum ceramides and sphingomyelin (SM) in a large cohort, revealing an association between the accumulation of circulating ceramides and disturbed ceramide/SM cycles during the progression of RA...
December 1, 2023: Journal of Proteome Research
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
